메뉴 건너뛰기




Volumn 196, Issue 11, 2017, Pages 1488-1489

Benefit of the shorter multidrug-resistant tuberculosis treatment regimen in California and modified eligibility criteria

Author keywords

[No Author keywords available]

Indexed keywords

TUBERCULOSTATIC AGENT;

EID: 85038119086     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201701-0013LE     Document Type: Letter
Times cited : (7)

References (9)
  • 1
    • 84992382894 scopus 로고    scopus 로고
    • Eligibility for the shorter multidrug-resistant tuberculosis regimen: Ambiguities in the World Health Organization recommendations [letter
    • Varaine F, Guglielmetti L, Huerga H, Bonnet M, Kiria N, Sitienei JK, Rich M, Mitnick CD. Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations [letter]. Am J Respir Crit Care Med 2016;194:1028–1029.
    • (2016) Am J Respir Crit Care Med , vol.194 , pp. 1028-1029
    • Varaine, F.1    Guglielmetti, L.2    Huerga, H.3    Bonnet, M.4    Kiria, N.5    Sitienei, J.K.6    Rich, M.7    Mitnick, C.D.8
  • 5
    • 84954510585 scopus 로고    scopus 로고
    • Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: Genes, mutations, and causalities
    • MGM2–MGM0014-2013
    • Vilchèze C, Jacobs WR Jr. Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities. Microbiol Spectr 2014;2:MGM2–MGM0014-2013.
    • (2014) Microbiol Spectr , vol.2
    • Vilchèze, C.1    Jacobs, W.R.2
  • 6
    • 38949175355 scopus 로고    scopus 로고
    • A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis
    • Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139–145.
    • (2008) Int J Tuberc Lung Dis , vol.12 , pp. 139-145
    • Katiyar, S.K.1    Bihari, S.2    Prakash, S.3    Mamtani, M.4    Kulkarni, H.5
  • 7
    • 84947422751 scopus 로고    scopus 로고
    • High prevalence of inha promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa
    • Niehaus AJ, Mlisana K, Gandhi NR, Mathema B, Brust JC. High prevalence of inha promoter mutations among patients with drug-resistant tuberculosis in KwaZulu-Natal, South Africa. Plos One 2015; 10:e0135003.
    • (2015) Plos One , vol.10
    • Niehaus, A.J.1    Mlisana, K.2    Gandhi, N.R.3    Mathema, B.4    Brust, J.C.5
  • 8
    • 84987710871 scopus 로고    scopus 로고
    • World Health Organization. Annexes 4, 5, and 6. Geneva, Switzerland: WHO Document Production Services
    • World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. Annexes 4, 5, and 6. Geneva, Switzerland: WHO Document Production Services; 2016.
    • (2016) WHO Treatment Guidelines for Drug-Resistant Tuberculosis. 2016 Update.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.